INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 237S237 trades$57.36M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03SJSheena Jonathan0B / 57S57 trades$3.61M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 32S32 trades$5.48M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

71,432 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GW
Go WilliamChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
44.0K sh
Feb 2, 2026Feb 4, 2026
Page 1351 of 1786
← PrevNext →
traded Feb 2, 2026
+2d
SEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Option exercise
M—
7,019 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
DV
Dixon Jonathan V.GENERAL COUNSEL
BNGOBionano Genomics, Inc.
Grant or award
A—
26.1K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Grant or award
A—
5,673 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
HY
Howze YalondaINTERIM CEO & PRESIDENT
GBIOGeneration Bio Co.
Option exercise
M—
1,673 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
RP
Regan John PSEVP, Chief Risk Officer
VLYVALLEY NATIONAL BANCORP
Tax withholding
F$23K
1,835 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
BS
Bohen SeanDirector, PRESIDENT AND CEO
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
850.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
HD
Honorable Colette DEVP CLO Compliance & Corp Sec
EXCEXELON CORP
Grant or award
A—
12.8K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
KJ
Kim Peter Sung-JipSVP & GM Industrial Business
LFUSLITTELFUSE INC /DE
Option exercise
M—
5,488 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
AM
Adamchak MarkPrincipal Accounting Officer
BNGOBionano Genomics, Inc.
Grant or award
A—
10.9K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
TP
Torres Isaac P.Director
SRCE1ST SOURCE CORP
Grant or award
A$14K
212 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

9
LF
Link David ForrestDirector
APPNAPPIAN CORP
Grant or award
A—
771 sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

9
SK
Shaikh KashifDirector, President and CEO
PENGPenguin Solutions, Inc.
Grant or award
A—
238.2K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
GW
Go WilliamChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
154.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$8,830
200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
NA
Novack Jeffrey AdamSecretary and General Counsel
CDNACareDx, Inc.
Tax withholding
F$51K
2,492 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
FJ
Fox-Geen JeremyChief Financial Officer
CRCLCircle Internet Group, Inc.
Tax withholding
F$248K
3,877 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Tax withholding
F$537K
8,404 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
NA
Novack Jeffrey AdamSecretary and General Counsel
CDNACareDx, Inc.
Tax withholding
F$61K
2,970 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
OO
Okupe OluyemiChief Financial Officer
HIMSHims & Hers Health, Inc.
Open-market sale · 10b5-1 plan
SELL$139K
5,262 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

8
GS
Gummadi SuryaPresident - Americas
CTSHCOGNIZANT TECHNOLOGY SOLUTIONS CORP
Open-market sale · 10b5-1 plan
SELL$144K
1,728 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

6
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$8,388
720 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

6
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
2,434 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

6
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$108K
10.0K sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

6
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$159K
14.7K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
NA
Novack Jeffrey AdamSecretary and General Counsel
CDNACareDx, Inc.
Grant or award
A—
4,342 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
SC
Saldanha CraigChief Product Officer
YELPYELP INC
Open-market sale · 10b5-1 plan
SELL$33K
1,200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Grant or award
A—
150.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
RG
Russotti GregorySee Remarks
IPSCCentury Therapeutics, Inc.
Grant or award
A—
265.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
ZN
Zojwalla NaseemCHIEF MEDICAL OFFICER
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
106.3K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
HL
Heeson LeeEVP, Head of Incyte Intl
INCYINCYTE CORP
Tax withholding
F$11K
111 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
CT
Chuang Patrick T.Senior VP, Memory Design
GSITGSI TECHNOLOGY INC
Grant or award
A—
20.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
ZN
Zojwalla NaseemCHIEF MEDICAL OFFICER
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
250.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
PB
Pfeiffenberger BrentDirector, President and CEO
IPSCCentury Therapeutics, Inc.
Grant or award
A—
945.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NP
Naude PierreDirector
NCNOnCino, Inc.
Grant or award
A—
3,516 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$6,477
2,540 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence